Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Subscribe To Our Newsletter & Stay Updated
